Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00290251 · ClinicalTrials.gov registry record · Phase 2
Treatment of Uterine Fibroids With the Selective Progesterone Receptor Modulator CDB-2914
A Phase 2 study of Leiomyoma, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Completed
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
- 2
- Study locations
NCT00290251 is a Phase 2 study of Leiomyoma that has completed, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 72 participants, below the 97-participant average among 8 other Leiomyoma trials with a reported enrollment target (26% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT00290251, a Phase 2 study of Leiomyoma, has completed, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study will evaluate whether the experimental drug ulipristal acetate can shrink uterine fibroids in pre-menopausal women.
Conditions Studied
Interventions
- DRUG placebo
- DRUG ulipristal acetate 20 mg
- DRUG ulipristal acetate 10 mg
Study Locations (2)
Maryland
- NIH Clinical Center - Bethesda
- National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2006-02 |
| Est. Completion | 2010-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00290251
The ClinicalTrials.gov registry entry for NCT00290251 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 97-participant average among 8 other Leiomyoma trials with a reported enrollment target (26% lower). The listed sponsor is National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Leiomyoma appearing as the primary indexed condition, and to 3 interventions - of which placebo is the first listed.
NCT00290251 reports 2 study locations spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00290251 about?
NCT00290251 is a clinical study titled "Treatment of Uterine Fibroids With the Selective Progesterone Receptor Modulator CDB-2914". This study will evaluate whether the experimental drug ulipristal acetate can shrink uterine fibroids in pre-menopausal women.
What is the current status of trial NCT00290251?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2006-02. Estimated completion is 2010-08.
What conditions does trial NCT00290251 study?
This clinical trial studies the following conditions: Leiomyoma.
What interventions are being tested in trial NCT00290251?
The interventions under investigation include: placebo (DRUG), ulipristal acetate 20 mg (DRUG), ulipristal acetate 10 mg (DRUG).
Who is sponsoring clinical trial NCT00290251?
This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00290251 being conducted?
This trial has 2 study locations across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leiomyoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effects of Simvastatin on Uterine Leiomyoma Size
RECRUITING · Phase 2
-
Treatment of Uterine Fibroids With CDB-2914, an Experimental Selective Progesterone Receptor Antagonist
COMPLETED · Phase 2
-
An Open-Label Study to Evaluate the Effect of Elix Cycle Balance & Elix Daily Harmony on Fibroid-related Symptoms
RECRUITING · NA
-
Role of Senescent Cells in Uterine Fibroid Pathogenesis (SOUL Study)
RECRUITING
-
Prescription of Letrozole for Uterine Myoma
RECRUITING · Phase 4
-
Surgical Success After Laparoscopic vs Abdominal Hysterectomy
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.